The leading innovative drug company frequently reports good news, with solid innovation reinforcing long-term value

In May 2026, the global radiation oncology conference ESTRO was held in Stockholm, where United Imaging Healthcare showcased its "Smart Radiotherapy Ecosystem" in Europe. This appearance was not just about the export of a single product, but rather a comprehensive ecological closed-loop output covering the entire process from "simulation positioning - AI delineation - automatic planning - quality control - treatment." Its core product, the uRT-linac 506c integrated machine, has passed the EU's most stringent CE MDR certification thanks to its pioneering diagnostic-grade CT and linear accelerator fusion technology. This not only proves United Imaging's unique global self-research capabilities across the three fields of imaging, AI, and radiotherapy equipment but also marks a significant shift for China's high-end medical devices from "product export" to high-dimensional "ecological output." The company has already established strategic partnerships with top medical institutions in Italy, France, and other regions. At the same time, leading innovative drug company BeOne Medicines has also reported good news regarding its research pipeline. According to the latest announcement from the CDE, the clinical trial application for the new indication of the Class 1 new drug BG-75202 tablets was granted implied approval on May 20, 2026, intended for the treatment of myeloid malignancies. BG-75202 is a highly selective KAT6A/B inhibitor, primarily targeting tumor resistance mechanisms. Preclinical studies have shown that this product outperforms similar competitors in terms of efficacy and safety. KAT6 abnormalities are one of the main culprits causing patients with breast cancer, leukemia, and other conditions to develop resistance to existing therapies. Currently, no drugs targeting this site have been approved for market release globally, and BeOne Medicines is at the forefront of advancements in this field. Whether it is United Imaging's ecological reconstruction in the high-end intelligent manufacturing sector or BeOne Medicines' precise targeting of cutting-edge targets, both reflect the leap of China's leading medical enterprises from following and imitating to original innovation. This competitive barrier based on breakthroughs in underlying technologies provides a solid guarantee for their continued growth in the global market. Related ETFs: Kechuang Medical ETF Huaxia (588130), Connect A/C: 027142/027143 Kechuang Medical ETF Huaxia (588130) tracks the Kechuang Biotech Index (000683.SH), with the top three weighted industries being medical devices + chemical pharmaceuticals + biological products, over 90% of the weight is allocated to core segments of pharmaceutical innovation, and it features a 20% fluctuation elasticity of the STAR Market. United Imaging Healthcare and BeOne Medicines are both among the top ten weighted stocks